Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
about
Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices.Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.Clinical application of DNA ploidy to cervical cancer screening: A review.HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancerA study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening resultsComparison of the Cobas 4800 HPV and HPV 9G DNA Chip Tests for Detection of High-Risk Human Papillomavirus in Cervical Specimens of Women with Consecutive Positive HPV Tests But Negative Pap Smears.Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.A Suggested Approach to Simplify and Improve Cervical Screening in the United States.Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recallTriage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancerPrimary cervical cancer screening with an HPV mRNA test: a prospective cohort study.Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean populationFactors influencing decisions about surgical treatment of cervical precancerous lesions.A cohort study of cervical screening using partial HPV typing and cytology triage.Influence of Human Papillomavirus Infection on the Natural History of Cervical Intraepithelial Neoplasia 1: A Meta-Analysis.Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?Risk assessment to guide cervical screening strategies in a large Chinese population.Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women.Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach.Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: Contributing factors and role of human papillomavirus genotyping.
P2860
Q30487807-91E06EB6-704C-4342-97F9-20654F45B19FQ33951517-5319783F-1921-425A-986B-7EBE3188684FQ34657755-4D424097-9CB4-4A91-80FC-C6F32B58371CQ34675069-37A8B50F-87FC-483E-9F73-632A880206FCQ34916671-70E8ED55-86E4-411D-9F68-687D4227F7BDQ35808851-00BA9C43-AAB1-4914-B18A-A97F7E6D0671Q36187634-DFC1D574-6619-46AE-89EA-DDC5EA7F2BC2Q36254941-D09F9496-2A0D-43BB-8319-9752895B695FQ36407125-8D96E319-A91C-4394-80ED-73328AC4DA71Q36511847-0ECF5085-0D66-4368-8290-9F3790EE2313Q36803663-EE0F8006-D682-4409-BC45-EEFE86F785B5Q37177735-F59BA2B2-872D-483F-AE43-DA65AD3FA427Q37655869-2EF1F89B-A544-42CC-98F7-586D8A421168Q38190107-28BBE51C-1C13-45EA-9484-00BB5E43A729Q38378838-E0775F63-9C83-443B-8E70-0BCF46902C65Q40091798-97AF42D9-DD91-4018-8DEA-5C612C5154C7Q40155311-95F6D345-3788-493F-B117-5B6F54DF2751Q40717962-359FEA62-9D2E-435A-BA64-B68D33D2A46CQ40821522-63136CF9-457D-411F-97DE-8059ACC2977FQ40854884-A530F687-CD93-45F9-A78F-6A17005D2B42Q42239534-A29CE3E0-9F69-463F-8B91-4C876616DA09Q42369427-3926985C-D9D3-4006-9B12-C2C1147B5B73Q46075408-064B7C9E-C4D0-4D82-89C4-2C3BD7551758Q46335294-FD131F8E-4A3A-4335-8B9D-4A2CC7714E41Q47566800-6FB7098E-00AD-44DC-9361-73510B7F5269
P2860
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@ast
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@en
type
label
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@ast
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@en
prefLabel
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@ast
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@en
P2093
P2860
P1476
Five-year risks of CIN 3+ and ...... negative but are HPV-positive.
@en
P2093
Barbara Fetterman
Hormuzd A Katki
Julia C Gage
Li C Cheung
Nancy E Poitras
Philip E Castle
Thomas Lorey
Tina Raine-Bennett
Walter K Kinney
P2860
P304
P356
10.1097/LGT.0B013E318285437B
P433
P577
2013-04-01T00:00:00Z